GOQii Partners with Acrannolife Genomics to Launch GrafCare Program
Thursday, 06 February 2025, 11:22 IST
GOQii in collaboration with Acrannolife Genomics launched the GrafCare Program an innovative initiative toward transforming post-transplant care in India. Through the integration of advanced genomic diagnostics, AI, and personalized health monitoring, this program aims at enhancing the quality of life and health outcomes of organ recipients.
Post-transplant care remains a critical yet underserved segment in healthcare. The GrafCare Program addresses this gap by combining Acrannolife’s US-patented Trunome test with GOQii’s smart health ecosystem. This integration enables early detection of complications, real-time health monitoring, and tailored patient support to improve long-term recovery.
Acrannolife’s Trunome test is a non-invasive blood test designed to detect early signs of organ rejection or infection. Using the latest genomic research and AI-powered analytics, the test provides accurate, actionable insights, so clinicians can intervene before complications become more serious. The patients participating in the program receive a GOQii Smart Vital Device, which continuously tracks the vital health parameters of heart rate, blood pressure, and oxygen levels. Predictive analytics by AI assesses patient data to generate early alerts and personalized health recommendations, allowing for proactive medical interventions.
It goes beyond just diagnostics and monitoring with holistic support. A patient has available nutritionists and counseling for the designing of a customized recovery based on genetic profiling and health data. Preventive care minimizes dependence on reactive medical treatments that may impede the smooth process of recovery.
GrafCare offers financial support to make advanced care more accessible. The interest-free loan for up to one year, discounts on immunosuppressants, and free diagnostic tests like Tacrolimus and kidney/liver function tests are provided. This makes the financial burden lighter, allowing the transplant recipient to focus on recovery without added stress.
“This is more than a health program; it’s a lifeline for transplant recipients”, said Vishal Gondal, Founder & CEO of GOQii. “With GrafCare, we’re leveraging AI and genomics to empower both patients and clinicians, bringing a new level of care that was previously unattainable”.
Agragesh Ramani, Co-founder Acrannolife Genomics, shared the following: "Having gone through the transplant experience within my family, I realized the plight of the patients. GrafCare enables early and precise detection of organ rejection, and thus transplant patients can heal and live their life to the fullest without financial worries".
The GrafCare Program marks a significant advancement in post-transplant care, offering patients cutting-edge technology, expert guidance, and financial support to navigate their recovery journey effective
Post-transplant care remains a critical yet underserved segment in healthcare. The GrafCare Program addresses this gap by combining Acrannolife’s US-patented Trunome test with GOQii’s smart health ecosystem. This integration enables early detection of complications, real-time health monitoring, and tailored patient support to improve long-term recovery.
Acrannolife’s Trunome test is a non-invasive blood test designed to detect early signs of organ rejection or infection. Using the latest genomic research and AI-powered analytics, the test provides accurate, actionable insights, so clinicians can intervene before complications become more serious. The patients participating in the program receive a GOQii Smart Vital Device, which continuously tracks the vital health parameters of heart rate, blood pressure, and oxygen levels. Predictive analytics by AI assesses patient data to generate early alerts and personalized health recommendations, allowing for proactive medical interventions.
It goes beyond just diagnostics and monitoring with holistic support. A patient has available nutritionists and counseling for the designing of a customized recovery based on genetic profiling and health data. Preventive care minimizes dependence on reactive medical treatments that may impede the smooth process of recovery.
GrafCare offers financial support to make advanced care more accessible. The interest-free loan for up to one year, discounts on immunosuppressants, and free diagnostic tests like Tacrolimus and kidney/liver function tests are provided. This makes the financial burden lighter, allowing the transplant recipient to focus on recovery without added stress.
“This is more than a health program; it’s a lifeline for transplant recipients”, said Vishal Gondal, Founder & CEO of GOQii. “With GrafCare, we’re leveraging AI and genomics to empower both patients and clinicians, bringing a new level of care that was previously unattainable”.
Agragesh Ramani, Co-founder Acrannolife Genomics, shared the following: "Having gone through the transplant experience within my family, I realized the plight of the patients. GrafCare enables early and precise detection of organ rejection, and thus transplant patients can heal and live their life to the fullest without financial worries".
The GrafCare Program marks a significant advancement in post-transplant care, offering patients cutting-edge technology, expert guidance, and financial support to navigate their recovery journey effective
